"Achieve Life Sciences received a Complete Response Letter (CRL) from the FDA regarding its cytisinicline NDA. The CRL cites manufacturing deficiencies at a third-party facility, not clinical safety or efficacy issues. The company plans to resubmit the NDA in Q4 2026 with a new manufacturing partner."